Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Mantle Cell Lymphoma-Pipeline Review, H1 2015

Mantle Cell Lymphoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Mantle Cell Lymphoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Mantle Cell Lymphoma-Pipeline Review, H1 2015', provides an overview of the Mantle Cell Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Mantle Cell Lymphoma Overview 9

Therapeutics Development 10

Pipeline Products for Mantle Cell Lymphoma-Overview 10

Pipeline Products for Mantle Cell Lymphoma-Comparative Analysis 11

Mantle Cell Lymphoma-Therapeutics under Development by Companies 12

Mantle Cell Lymphoma-Therapeutics under Investigation by Universities/Institutes 16

Mantle Cell Lymphoma-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Mantle Cell Lymphoma-Products under Development by Companies 20

Mantle Cell Lymphoma-Products under Investigation by Universities/Institutes 24

Mantle Cell Lymphoma-Companies Involved in Therapeutics Development 25

AbbVie Inc. 25

Accentia Biopharmaceuticals, Inc. 26

Actinium Pharmaceuticals, Inc. 27

Advancell 28

Affimed Therapeutics AG 29

Amgen Inc. 30

Astellas Pharma Inc. 31

Astex Pharmaceuticals, Inc. 32

Bayer AG 33

Bristol-Myers Squibb Company 34

Celgene Corporation 35

Celldex Therapeutics, Inc. 36

Eisai Co., Ltd. 37

Eli Lilly and Company 38

EpiZyme, Inc. 39

Gilead Sciences, Inc. 40

GlaxoSmithKline plc 41

ImmunoGen, Inc. 42

Incyte Corporation 43

Infinity Pharmaceuticals, Inc. 44

Johnson & Johnson 45

Karyopharm Therapeutics, Inc. 46

Kite Pharma, Inc. 47

MedImmune, LLC 48

Merck & Co., Inc. 49

Millennium Pharmaceuticals, Inc. 50

MorphoSys AG 51

Nordic Nanovector AS 52

Novartis AG 53

Onconova Therapeutics, Inc. 54

Onyx Pharmaceuticals, Inc. 55

Pfizer Inc. 56

Pharmacyclics, Inc. 57

Portola Pharmaceuticals, Inc. 58

Seattle Genetics, Inc. 59

Sevion Therapeutics, Inc. 60

Stemline Therapeutics, Inc. 61

Teva Pharmaceutical Industries Limited 62

TG Therapeutics, Inc. 63

Mantle Cell Lymphoma-Therapeutics Assessment 64

Assessment by Monotherapy Products 64

Assessment by Combination Products 65

Assessment by Target 66

Assessment by Mechanism of Action 69

Assessment by Route of Administration 72

Assessment by Molecule Type 74

Assessment by Molecule Type 74

Drug Profiles 76

13197-Drug Profile 76

abemaciclib-Drug Profile 78

abexinostat hydrochloride-Drug Profile 79

acadesine-Drug Profile 81

ACP-196-Drug Profile 83

AFM-11-Drug Profile 84

agatolimod sodium-Drug Profile 85

alisertib-Drug Profile 88

AMG-319-Drug Profile 92

AT-7519-Drug Profile 93

bendamustine hydrochloride-Drug Profile 96

Betalutin-Drug Profile 99

blinatumomab-Drug Profile 101

BLyS-gel-Drug Profile 104

BMS-986016-Drug Profile 105

bortezomib-Drug Profile 106

buparlisib hydrochloride-Drug Profile 112

carfilzomib-Drug Profile 116

CC-122-Drug Profile 120

Cell Therapy for Oncology-Drug Profile 122

Cell Therapy to Target CD19 for Oncology-Drug Profile 123

Cell Therapy to Target CD19 for Oncology-Drug Profile 124

Cell Therapy to Target CD20 for Chemotherapy Resistant Cancers-Drug Profile 125

CEP-9722-Drug Profile 126

cerdulatinib-Drug Profile 127

copanlisib-Drug Profile 128

dasiprotimut-T-Drug Profile 131

denintuzumab mafodotin-Drug Profile 133

duvelisib-Drug Profile 134

E-7449-Drug Profile 136

EPZ-015666-Drug Profile 137

FROST-400-Drug Profile 138

GS-9973-Drug Profile 139

ibrutinib-Drug Profile 140

ibrutinib + ublituximab + TGR-1202-Drug Profile 146

idelalisib-Drug Profile 147

IMGN-529-Drug Profile 150

INA-01-Drug Profile 151

INCB-39110-Drug Profile 152

INCB-40093-Drug Profile 154

ixazomib citrate-Drug Profile 155

KTE-C19 CAR-Drug Profile 158

lenalidomide-Drug Profile 160

MEDI-0680-Drug Profile 164

MEDI-551-Drug Profile 165

MGD-011-Drug Profile 167

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies-Drug Profile 168

Monoclonal Antibody Conjugate to Target CD45 for Oncology-Drug Profile 169

MOR-208-Drug Profile 170

moxetumomab pasudotox-Drug Profile 172

ON-123300-Drug Profile 174

palbociclib-Drug Profile 175

pevonedistat hydrochloride-Drug Profile 179

ribociclib-Drug Profile 181

selinexor-Drug Profile 184

SGN-CD70A-Drug Profile 188

SL-101-Drug Profile 189

SNS-01T-Drug Profile 190

sotrastaurin acetate-Drug Profile 191

TGR-1202-Drug Profile 193

tisagenlecleucel-T-Drug Profile 195

tretinoin-Drug Profile 197

ublituximab-Drug Profile 198

varlilumab-Drug Profile 200

venetoclax-Drug Profile 202

vorinostat-Drug Profile 205

Mantle Cell Lymphoma-Recent Pipeline Updates 209

Mantle Cell Lymphoma-Dormant Projects 314

Mantle Cell Lymphoma-Discontinued Products 316

Mantle Cell Lymphoma-Product Development Milestones 317

Featured News & Press Releases 317

Appendix 330

Methodology 330

Coverage 330

Secondary Research 330

Primary Research 330

Expert Panel Validation 330

Contact Us 330

Disclaimer 331

List of Tables

Number of Products under Development for Mantle Cell Lymphoma, H1 2015 15

Number of Products under Development for Mantle Cell Lymphoma-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Development by Companies, H1 2015 (Contd..3) 28

Products under Investigation by Universities/Institutes, H1 2015 29

Mantle Cell Lymphoma-Pipeline by AbbVie Inc., H1 2015 30

Mantle Cell Lymphoma-Pipeline by Accentia Biopharmaceuticals, Inc., H1 2015 31

Mantle Cell Lymphoma-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 32

Mantle Cell Lymphoma-Pipeline by Advancell, H1 2015 33

Mantle Cell Lymphoma-Pipeline by Affimed Therapeutics AG, H1 2015 34

Mantle Cell Lymphoma-Pipeline by Amgen Inc., H1 2015 35

Mantle Cell Lymphoma-Pipeline by Astellas Pharma Inc., H1 2015 36

Mantle Cell Lymphoma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 37

Mantle Cell Lymphoma-Pipeline by Bayer AG, H1 2015 38

Mantle Cell Lymphoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 39

Mantle Cell Lymphoma-Pipeline by Celgene Corporation, H1 2015 40

Mantle Cell Lymphoma-Pipeline by Celldex Therapeutics, Inc., H1 2015 41

Mantle Cell Lymphoma-Pipeline by Eisai Co., Ltd., H1 2015 42

Mantle Cell Lymphoma-Pipeline by Eli Lilly and Company, H1 2015 43

Mantle Cell Lymphoma-Pipeline by EpiZyme, Inc., H1 2015 44

Mantle Cell Lymphoma-Pipeline by Gilead Sciences, Inc., H1 2015 45

Mantle Cell Lymphoma-Pipeline by GlaxoSmithKline plc, H1 2015 46

Mantle Cell Lymphoma-Pipeline by ImmunoGen, Inc., H1 2015 47

Mantle Cell Lymphoma-Pipeline by Incyte Corporation, H1 2015 48

Mantle Cell Lymphoma-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 49

Mantle Cell Lymphoma-Pipeline by Johnson & Johnson, H1 2015 50

Mantle Cell Lymphoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 51

Mantle Cell Lymphoma-Pipeline by Kite Pharma, Inc., H1 2015 52

Mantle Cell Lymphoma-Pipeline by MedImmune, LLC, H1 2015 53

Mantle Cell Lymphoma-Pipeline by Merck & Co., Inc., H1 2015 54

Mantle Cell Lymphoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 55

Mantle Cell Lymphoma-Pipeline by MorphoSys AG, H1 2015 56

Mantle Cell Lymphoma-Pipeline by Nordic Nanovector AS, H1 2015 57

Mantle Cell Lymphoma-Pipeline by Novartis AG, H1 2015 58

Mantle Cell Lymphoma-Pipeline by Onconova Therapeutics, Inc., H1 2015 59

Mantle Cell Lymphoma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 60

Mantle Cell Lymphoma-Pipeline by Pfizer Inc., H1 2015 61

Mantle Cell Lymphoma-Pipeline by Pharmacyclics, Inc., H1 2015 62

Mantle Cell Lymphoma-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 63

Mantle Cell Lymphoma-Pipeline by Seattle Genetics, Inc., H1 2015 64

Mantle Cell Lymphoma-Pipeline by Sevion Therapeutics, Inc., H1 2015 65

Mantle Cell Lymphoma-Pipeline by Stemline Therapeutics, Inc., H1 2015 66

Mantle Cell Lymphoma-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 67

Mantle Cell Lymphoma-Pipeline by TG Therapeutics, Inc., H1 2015 68

Assessment by Monotherapy Products, H1 2015 69

Assessment by Combination Products, H1 2015 70

Number of Products by Stage and Target, H1 2015 72

Number of Products by Stage and Mechanism of Action, H1 2015 75

Number of Products by Stage and Route of Administration, H1 2015 78

Number of Products by Stage and Molecule Type, H1 2015 80

Mantle Cell Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 214

Mantle Cell Lymphoma-Dormant Projects, H1 2015 319

Mantle Cell Lymphoma-Dormant Projects (Contd..1), H1 2015 320

Mantle Cell Lymphoma-Discontinued Products, H1 2015 321

List of Figures

Number of Products under Development for Mantle Cell Lymphoma, H1 2015 15

Number of Products under Development for Mantle Cell Lymphoma-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Products, H1 2015 24

Assessment by Monotherapy Products, H1 2015 69

Number of Products by Top 10 Targets, H1 2015 71

Number of Products by Stage and Top 10 Targets, H1 2015 71

Number of Products by Top 10 Mechanism of Actions, H1 2015 74

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 74

Number of Products by Top 10 Routes of Administration, H1 2015 77

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 77

Number of Products by Top 10 Molecule Types, H1 2015 79

Number of Products by Stage and Top 10 Molecule Types, H1 2015 79

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Accentia Biopharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Advancell

Affimed Therapeutics AG

Amgen Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

Bayer AG

Bristol-Myers Squibb Company

Celgene Corporation

Celldex Therapeutics, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

EpiZyme, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline plc

ImmunoGen, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

MorphoSys AG

Nordic Nanovector AS

Novartis AG

Onconova Therapeutics, Inc.

Onyx Pharmaceuticals, Inc.

Pfizer Inc.

Pharmacyclics, Inc.

Portola Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Sevion Therapeutics, Inc.

Stemline Therapeutics, Inc.

Teva Pharmaceutical Industries Limited

TG Therapeutics, Inc.

Mantle Cell Lymphoma Therapeutic Products under Development, Key Players in Mantle Cell Lymphoma Therapeutics, Mantle Cell Lymphoma Pipeline Overview, Mantle Cell Lymphoma Pipeline, Mantle Cell Lymphoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com